The present invention relates to the treatment of disorders associated with oxidative stress including neuropathic pain and small synthetically derived compounds for treating such disorders.

The present invention relates to an improved synthesis and crystallization process of the 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, also known as nitisinone or NTBC.

The present invention relates to an improved synthesis and crystallization process of the 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, also known as nitisinone or NTBC.

Provided herein are naphthoquinones compounds such as those with a hydrogen bond donating group of the formula (I): wherein: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and n are as defined herein. Also provided herein are pharmaceutical composition of the present compounds and methods of treatment using the compounds including their use in the treatment of cancer. ##STR00001##

Provided herein are naphthoquinones compounds such as those with a hydrogen bond donating group of the formula (I): wherein: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and n are as defined herein. Also provided herein are pharmaceutical composition of the present compounds and methods of treatment using the compounds including their use in the treatment of cancer. ##STR00001##

Disclosed herein are new pharmacological therapies that increase CYB5R3 activity, improve vascular function and limit inflammation by restoring the redox balance in CVD. In one embodiment, disclosed herein are compounds that include an alkyl chain containing a nitroalkene group conjugated to a quinone-containing moiety.

Disclosed herein are new pharmacological therapies that increase CYB5R3 activity, improve vascular function and limit inflammation by restoring the redox balance in CVD. In one embodiment, disclosed herein are compounds that include an alkyl chain containing a nitroalkene group conjugated to a quinone-containing moiety.

Provided herein are naphthoquinones compounds such as those with a hydrogen bond donating group of the formula (I): wherein: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and n are as defined herein. Also provided herein are pharmaceutical composition of the present compounds and methods of treatment using the compounds including their use in the treatment of cancer.

##STR00001##

The present invention relates to an improved synthesis and crystallization process of the 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, also known as nitisinone or NTBC.

The present invention relates to an improved synthesis and crystallization process of the 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, also known as nitisinone or NTBC.